ADMA Biologics, Inc. (ADMA)

ADMA exhibits strong commercial-biologics fundamentals with high trailing profitability (TTM gross margin ~64.71%, net margin ~32.98%) and attractive capital returns (ROIC ~27.55%). The latest SEC filings show ample liquidity (cash ~136M, current ratio ~6.97) and modest leverage (net debt/EBITDA ~0.29) with disclosed covenant compliance and no explicit going‑concern language. Valuation looks reasonable (P/E ~12.67, EV/EBITDA ~9.56, FCF yield ~5.35%), but investors should keep focus on customer concentration and FDA/cGMP execution risk.

The dominant near-term driver is the filed federal securities class action alleging channel-stuffing, an undisclosed related-party transaction, and inadequate internal controls (Mazzarino v. ADMA Biologics, No. 26-cv-06918, D.N.J.), whose early-August ~29% stock drop still anchors a bearish tape; the sentiment delta is determinate deterioration at item level (moderate confidence — the scoring-window aggregate was unmeasured), retail engagement is absent, and the Red-Flag Screen fired two moderate flags (confirmed litigation with court-docket confirmation; sharp ≤14d sentiment deterioration with no offsetting bullish catalyst) — moderate red-flag cap applied.

Price 9.14 sits below SMA20 (9.52), SMA50 (9.22) and the declining SMA200 (12.46), and below EMA9/21 (9.38/9.42). ADX 54.7 signals a very strong trend, but with price under every major average the trend strength is bearish, not bullish. RSI 43.1 has rolled down from ~55 a week ago, MACD line (0.01) is under its signal (0.08) with a negative histogram (-0.07), and the last two sessions closed lower on rising volume — weak momentum. Williams %R -89.9 is deeply oversold, which supports at most a reflex bounce, not a trend-following long. Chart quality is weak bearish/bounce-only.